Vident Investment Advisory LLC Acquires 60,608 Shares of Five Prime Therapeutics Inc (FPRX)

Share on StockTwits

Vident Investment Advisory LLC raised its holdings in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 74.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,154 shares of the biotechnology company’s stock after buying an additional 60,608 shares during the period. Vident Investment Advisory LLC owned about 0.40% of Five Prime Therapeutics worth $2,247,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Rockefeller Capital Management L.P. bought a new position in shares of Five Prime Therapeutics in the first quarter valued at $111,000. Quantbot Technologies LP raised its holdings in shares of Five Prime Therapeutics by 361.5% in the first quarter. Quantbot Technologies LP now owns 7,347 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 5,755 shares during the last quarter. Mackay Shields LLC purchased a new stake in shares of Five Prime Therapeutics in the first quarter valued at about $317,000. Alambic Investment Management L.P. purchased a new stake in shares of Five Prime Therapeutics in the second quarter valued at about $351,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Five Prime Therapeutics in the second quarter valued at about $379,000. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ FPRX opened at $13.53 on Friday. Five Prime Therapeutics Inc has a 52-week low of $12.52 and a 52-week high of $48.87. The stock has a market cap of $511.63 million, a P/E ratio of -2.51 and a beta of 3.24.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.30. Five Prime Therapeutics had a negative net margin of 206.02% and a negative return on equity of 40.61%. The business had revenue of $7.58 million during the quarter, compared to the consensus estimate of $5.87 million. analysts forecast that Five Prime Therapeutics Inc will post -4.02 EPS for the current fiscal year.

Several analysts have recently commented on the stock. BidaskClub downgraded shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 26th. Leerink Swann assumed coverage on shares of Five Prime Therapeutics in a report on Thursday. They issued an “outperform” rating and a $24.00 target price for the company. ValuEngine downgraded shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, July 28th. JPMorgan Chase & Co. assumed coverage on shares of Five Prime Therapeutics in a report on Friday, June 15th. They issued a “neutral” rating and a $19.00 target price for the company. Finally, Wedbush increased their target price on shares of Five Prime Therapeutics from $17.00 to $19.00 and gave the company a “hold” rating in a report on Friday, August 10th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the stock. Five Prime Therapeutics presently has a consensus rating of “Hold” and an average price target of $31.70.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Read More: Growth Stocks

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MAM Software Group Inc.  Director William Austin Iv Lewis Sells 122,000 Shares
MAM Software Group Inc. Director William Austin Iv Lewis Sells 122,000 Shares
SG Americas Securities LLC Buys New Stake in RXi Pharmaceuticals Corp
SG Americas Securities LLC Buys New Stake in RXi Pharmaceuticals Corp
Graco Inc.  Holdings Reduced by Renaissance Technologies LLC
Graco Inc. Holdings Reduced by Renaissance Technologies LLC
Renaissance Technologies LLC Boosts Holdings in Urstadt Biddle Properties Inc
Renaissance Technologies LLC Boosts Holdings in Urstadt Biddle Properties Inc
GCP Applied Technologies Inc  Stake Increased by Russell Investments Group Ltd.
GCP Applied Technologies Inc Stake Increased by Russell Investments Group Ltd.
Cardtronics PLC  Shares Sold by Schwab Charles Investment Management Inc.
Cardtronics PLC Shares Sold by Schwab Charles Investment Management Inc.


Leave a Reply

 
© 2006-2018 Zolmax.